STOCK TITAN

IGC Pharma Inc - IGC STOCK NEWS

Welcome to our dedicated news page for IGC Pharma (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IGC Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IGC Pharma's position in the market.

Rhea-AI Summary
IGC-AD1's interim Phase 2 data shows a reduction in Alzheimer's agitation at week two, with a clinically significant reduction in agitation compared to placebo. The study achieves the secondary endpoint, demonstrating promising results in treating agitation in dementia due to Alzheimer's.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.45%
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. announces the addition of Dr. Pablo Arbelaez, an AI expert, to support the Phase 2 clinical trial of IGC-AD1 targeting agitation in Alzheimer's disease. The trial showed significant reduction in agitation, indicating strong therapeutic potential. Dr. Arbelaez will use AI to analyze disease signatures for personalized medicine, enhancing early detection methods for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
Rhea-AI Summary
IGC Pharma, Inc. (NYSE American: IGC) secures a $3 million strategic investment from Bradbury Asset Management, supporting the development of investigational medicines like IGC-AD1. The investment involves issuing 8,823,529 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
Rhea-AI Summary
IGC Pharma, Inc. announces positive interim results for IGC-AD1 in treating Agitation in dementia from Alzheimer’s Disease. The Phase 2 trial shows a significant reduction in agitation compared to placebo, with a Cohen’s d effect size of 0.66 and LS mean difference of -10.45. IGC-AD1 demonstrates potential as a transformative therapeutic option with a large market opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.91%
Tags
none
-
Rhea-AI Summary
IGC Pharma, Inc. announced CEO Ram Mukunda and VP Claudia Grimaldi's participation in a fire chat at Benzinga Virtual Healthcare Summit 2024. The company is making strides in Alzheimer's research with its novel therapy candidate IGC-AD1, moving from pre-clinical studies to phase two trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.91%
Tags
none
-
Rhea-AI Summary
IGC Pharma appoints Terry Lierman as independent director, bringing extensive healthcare experience to advance Alzheimer's disease treatments. Mr. Lierman's background in health care and strategic guidance will benefit the Company's Phase 2 trial for IGC-AD1 and preparation for TGR-63 Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
Rhea-AI Summary
IGC Pharma, Inc. announced positive results from preclinical studies on drug candidate TGR-63 for Alzheimer's disease. The data showed enhanced memory function in an Alzheimer's mouse model, targeting Aβ peptide misfolding and aggregation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary
IGC Pharma, Inc. announces analyst coverage report by Ascendiant Capital Markets LLC on their common stock. The report provides insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
Rhea-AI Summary
IGC Pharma, Inc. announces positive financial results and key developments in patents and partnerships for Q3 FY 2024, including advancements in pain treatment and Alzheimer's disease therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
IGC Pharma, Inc. announced positive results of preclinical studies for TGR-63, a potential treatment for Alzheimer's disease. The company aims to target a Phase 1 trial in 2024. TGR-63 showed positive impacts on plaque burden and anxiety reduction in transgenic Alzheimer's mouse models. The use of AI/ML tools is planned to accelerate the journey of TGR-63 from preclinical to patient care. CEO Ram Mukunda expressed enthusiasm and anticipation for clinical milestone updates throughout 2024 from the company's strengthened AD pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
IGC Pharma Inc

NYSE:IGC

IGC Rankings

IGC Stock Data

29.07M
56.96M
20.44%
3.71%
1.42%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Bethesda

About IGC

igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments